Table 3.
Proportion of Patients With ACR Responses in Week 24 by Observed Tocilizumab Ctrough Exposure Quartiles
| TCZ 162 mg SC QW | TCZ 162 mg SC Q2W | TCZ 8 mg/kg IV Q4W | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Q1 (n = 131) | Q2 (n = 129) | Q3 (n = 130) | Q4 (n = 129) | Q1 (n = 98) | Q2 (n = 98) | Q3 (n = 98) | Q4 (n = 97) | Q1 (n = 134) | Q2 (n = 135) | Q3 (n = 134) | Q4 (n = 131) | |
| ACR20 responders, n (%) | 82 (63) | 99 (76) | 95 (73) | 106 (82) | 41 (43) | 63 (64) | 70 (71) | 71 (73) | 101 (75) | 110 (81) | 108 (81) | 102 (78) |
| ACR50 responders, n (%) | 51 (39) | 67 (52) | 69 (53) | 69 (53) | 24 (24) | 40 (41) | 48 (49) | 50 (52) | 78 (58) | 69 (51) | 77 (57) | 59 (45) |
| ACR70 responders, n (%) | 26 (20) | 37 (28) | 36 (28) | 35 (27) | 8 (8) | 16 (16) | 29 (30) | 25 (26) | 46 (34) | 40 (30) | 43 (32) | 33 (25) |
| Mean (median) Ctrough, μg/mL | 14.6 (15.4) | 32.7 (33.1) | 47.9 (47.7) | 80.1 (72.5) | 0.1 (0.1) | 2.6 (2.4) | 7.6 (7.5) | 17.4 (16.5) | 4.1 (4.1) | 12.2 (12.0) | 20.2 (19.8) | 38.9 (36.9) |
Q1–Q4 refer to Ctrough exposure quartiles (lowest to highest). ACR, American College of Rheumatology; Ctrough, predose trough concentration; IV, intravenous; Q2W, every 2 weeks; Q4W, every 4 weeks; QW, weekly; SC, subcutaneous; TCZ, tocilizumab.